If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk ...
Zacks Investment Research on MSN
Here is what to know beyond why Johnson & Johnson (JNJ) is a trending stock
Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Zacks Investment Research on MSN
Johnson & Johnson (JNJ) stock drops despite market gains: Important facts to note
In the latest trading session, Johnson & Johnson (JNJ) closed at $204.31, marking a -1.47% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.64%. Elsewhere, ...
As an aside, see 3 Risks That Can Make UnitedHealth Stock Unattractive. Additionally, see: MSFT Stock A Winner In 2026? JNJ ...
Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares ...
Johnson & Johnson's (NYSE: JNJ) stock price is up more than 7% since the first trading day of November. What's going on with this healthcare giant? Well, J&J posted strong third-quarter results in mid ...
Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500. Barclays lifted its price target on Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 ...
The average one-year price target for Johnson & Johnson (WBAG:JNJ) has been revised to € 175,20 / share. This is an increase of 11.73% from the prior estimate of € 156,80 dated September 29, 2025. The ...
Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter ...
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and ...
J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment. 10 stocks we like better than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results